Patellar InstabilityNCT06932900
French Version of the Banff Patellar Instability Instrument 2.0
An observational study of Patellar Instability, run by Université de Sherbrooke at 1 site in Canada.
Trial summary
There are several treatment options for patellofemoral instability, but no established guidelines currently exist. An important step toward developing a consensus is to examine the influence of each intervention through the collection of both subjective and objective outcomes. Read more about this study
- Who is it for?
- Ages 14 years and older
- Conditions the study is for
- Patellar Instability
- How many people
- 52 participants
- Where
- 1 siteCanada
- Study dates
- 15 Nov 2021to Aug 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients consulting at the CHUS in Sherbrooke or at the Schriners Hospital in Montreal for patellar instability
Who may be able to join
- patient diagnosed with patellar instability with conservative or surgical treatment
- fluent in both spoken and written French
Who cannot join
- Patients who are unable to understand and/or respond to the questionnaire
- Patients with another diagnosis or knee pathology under study (e.g., complex ligament tear of the knee, gonarthrosis)
- Patients with another diagnosis or lower limb pathology under study with secondary functional impairment (e.g., coxarthrosis)
- Patients with a change in the condition of the lower limb under study a. Exclusion from test-retest reliability calculations if symptoms of patellofemoral instability worsen or if there is new involvement of this lower limb between T0 and T1 b. Exclusion from response to change calculations if new involvement of the lower limb (e.g., ipsilateral lower limb trauma) occurs after treatment, i.e., between T0 and T2
- Patients answering fewer than 19 questions (out of 23 questions)
Trial locations and contacts
1 site in 1 country.
Canada1 site
CIUSSS de l'Estrie-CHUS, 3001, 12e Ave Nord
Sherbrooke, Quebec, J1H5N4
About this study
Official title: French Translation and Validation of the Banff Patellar Instability Instrument 2.0
There are several treatment options for patellofemoral instability, but no established guidelines currently exist. An important step toward developing a consensus is to examine the influence of each intervention through the collection of both subjective and objective outcomes.
Most outcome measures commonly used for knee pathologies are primarily designed to monitor degenerative conditions (e.g., osteoarthritis) or ligamentous instability (e.g., anterior cruciate ligament rupture). Very few questionnaires are specific to patellar instability, a condition characterized by distinct signs and symptoms compared to other knee disorders.
Read more
The Banff Patellar Instability Instrument (BPII) was developed with this gap in mind, in accordance with the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) criteria. This condition-specific tool is designed to subjectively assess the functional impact of patellofemoral instability on patients' quality of life, which is the most important factor in evaluating treatment success.
Currently, there is no validated French-language outcome measure specific to patellofemoral instability. To improve patient care, the availability of such a validated tool in French is essential, both for clinical use and for conducting future research.
To address this issue, the primary objective of this study is to translate the Banff Patellar Instability Instrument 2.0 (BPII 2.0) into French, following the three-step process described in the IQOLA project and in accordance with the guidelines outlined by the American Academy of Orthopaedic Surgeons (AAOS), and to evaluate its validity in a French-speaking population.
Research Question Is the French version of the BPII 2.0 a valid tool to assess function in French-speaking patients diagnosed with patellofemoral instability?
Specific Objectives
To translate the Banff Patellar Instability Instrument 2.0 into French using a dual forward-backward translation process.
To evaluate the psychometric properties of the French version of the BPII 2.0, including its reliability and validity.
Read the detailed description
To address our primary outcome described above, an analytical observational design has been chosen as no intervention is applied to the subjects under study. The prospective study will confirm our hypothesis for objective 2, which is the validation of the questionnaire translated into French.
Study Population and Sample
The target population for this study consists of all patients with patellofemoral instability whose native language is French. Due to the difficulty of accessing such a large pool of patients, we will use an accessible population, specifically all French-speaking patients with patellofemoral instability who consult with an orthopedic surgeon at the Centre Hospitalier Universitaire de la Santé (CHUS) in Fleurimont, Hôtel-Dieu Hospital, or the Shriners Hospitals for Children - Canada in Montreal.
Selection Criteria
For the pre-test during the translation stage, all individuals aged 14 years or older, whose native language is French, are being followed for a knee condition at the CHUS outpatient clinic or Hôtel-Dieu Hospital, and who are willing to participate in the validation of the BPII 2.0 questionnaire translation will be included. No specific diagnosis of patellofemoral instability is required.
For the validation stage, the project will be presented to all patients at the CHUS Fleurimont, Hôtel-Dieu Hospital, or Shriners Hospitals for Children in Montreal, who are diagnosed with patellofemoral instability by an orthopedic surgeon and meet the criteria listed below. Patients with other pathologies of the affected lower limb or disease progression will be excluded to avoid confounding factors impacting functional quality of life. Also, those answering fewer than 19 questions will be excluded, as this corresponds to an invalid score according to studies of the test in English (4,6). To improve recruitment rates, we are making the project multicentric, and the orthopedic department at Shriners Hospitals for Children in Montreal will participate in the validation phase.
Inclusion Criteria
Patients aged 14 years and older with a new diagnosis of patellofemoral instability confirmed by an orthopedic surgeon
With conservative and/or surgical treatment
Patients fluent in both oral and written French
Exclusion Criteria
Patients who are unable to understand and/or respond to the questionnaire
Patients with another diagnosis or knee pathology under study (e.g., complex ligament tear, gonarthrosis)
Patients with another diagnosis or lower limb pathology under study with secondary functional impairment (e.g., coxarthrosis)
Patients with a change in the condition of the affected lower limb
Exclusion from test-retest reliability calculations if symptoms of patellofemoral instability worsen or new involvement of this lower limb occurs between T0 and T1
Exclusion from the response to change calculation if new involvement of the lower limb (e.g., ipsilateral lower limb trauma) occurs after treatment, i.e., between T0 and T2
Patients answering fewer than 19 questions (out of 23)
Sampling
To recruit eligible patients for the study, we will proceed with a non-probability convenience sampling approach.
For the first stage of translation (pre-test), all individuals who meet the criteria listed above will be included. For the second stage of validation, we will present the study to all patients who meet the selection criteria and present at the outpatient clinics of CHUS, Hôtel-Dieu Hospital, and Shriners Hospitals for Children in Montreal. This approach does not guarantee the representativeness of the population with patellofemoral instability, but it will not impact the validation of the functional measurement tool. This method will allow us to recruit a sufficient number of patients within a reasonable time frame. There are no confounding factors involved in the sampling of the population, as the goal of this study is the qualitative validation of the test, not measuring the treatment effect.
Recruitment
Participant recruitment will be on a voluntary basis. For the pre-test translation stage, patients will be recruited at the orthopedic outpatient clinic of CHUS Fleurimont or Hôtel-Dieu Hospital. For the validation stage, at the time of diagnosis, the orthopedic surgeon or resident at CHUS Fleurimont or Hôtel-Dieu Hospital who confirms patellofemoral instability will introduce the research project to the patient and verify if they meet the established selection criteria. If available at the participating center, the orthopedic surgeon or resident will have the patient sign a contact authorization form, if the research assistant is unavailable, to indicate whether the patient agrees to meet with the research assistant (Appendix 3). If the patient agrees to meet the research assistant, they will receive all relevant information about the research project. Together with the research assistant, the patient will be able to freely consent to their inclusion or exclusion from the research project by signing the informed consent form (refer to the consent form for the research project). In the case that the contact authorization form is unavailable, the research assistant will approach the patient after confirmation of the patellofemoral instability diagnosis during their clinic appointment.
- Conditions
- Patellar Instability
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| validation | person with patellar instability that will respond to the questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Questionnaire Banff Patellar Instability 2.0 Index in French
Questionnaire. (0-100 (0 = Worst, 100 = Best))
Measured: Baseline, 1 week and 6 month post intervention
Questionnaire Anterior Knee Pain Scale (Kujala)
Questionnaire. (0-100 (0 = Worst, 100 = Best))
Measured: Baseline and 6 month post intervention
Socio-Demographic
Age, Sex, Time since symptoms, Scolarship, Nationality
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2025
- Study start15 Nov 2021
- Primary completionAug 2025 (estimated)
- Study completionAug 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patellar InstabilityStudies of the same condition, open and under way.
- More trials run by Université de SherbrookeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 52 participants (actual)
Sponsor and investigators
- Lead sponsor
- Université de Sherbrooke
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, François Vézina, Université de Sherbrooke
- Investigators
- François Vézina, Doctor, Principal investigator, Université de Sherbrooke
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06932900
- Sponsor's protocol ID
- 2022-4329
- Status last verified
- Apr 2025
- First submitted
- 10 Apr 2025
- Last updated
- 17 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: This was not mention in the consent form as required in our REB. We could share the data on demand but not on public registry
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- French Translation and Validation of the Banff Patellar Instability Instrument 2.0
- ClinicalTrials.gov ID
- NCT06932900
- Acronym / sponsor ID
- 2022-4329
- Conditions
- Patellar Instability
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 52 participants (actual)
- Lead sponsor
- Université de SherbrookeUniversity, hospital or other
- Study start
- 15 Nov 2021 (actual)
- Primary completion
- Aug 2025 (estimated)
- Study completion
- Aug 2025 (estimated)
- First posted
- 17 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There are several treatment options for patellofemoral instability, but no established guidelines currently exist. An important step toward developing a consensus is to examine the influence of each intervention through the collection of both subjective and objective outcomes.
Most outcome measures commonly used for knee pathologies are primarily designed to monitor degenerative conditions (e.g., osteoarthritis) or ligamentous instability (e.g., anterior cruciate ligament rupture). Very few questionnaires are specific to patellar instability, a condition characterized by distinct signs and symptoms compared to other knee disorders.
The Banff Patellar Instability Instrument (BPII) was developed with this gap in mind, in accordance with the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) criteria. This condition-specific tool is designed to subjectively assess the functional impact of patellofemoral instability on patients' quality of life, which is the most important factor in evaluating treatment success.
Currently, there is no validated French-language outcome measure specific to patellofemoral instability. To improve patient care, the availability of such a validated tool in French is essential, both for clinical use and for conducting future research.
To address this issue, the primary objective of this study is to translate the Banff Patellar Instability Instrument 2.0 (BPII 2.0) into French, following the three-step process described in the IQOLA project and in accordance with the guidelines outlined by the American Academy of Orthopaedic Surgeons (AAOS), and to evaluate its validity in a French-speaking population.
Research Question Is the French version of the BPII 2.0 a valid tool to assess function in French-speaking patients diagnosed with patellofemoral instability?
Specific Objectives
To translate the Banff Patellar Instability Instrument 2.0 into French using a dual forward-backward translation process.
To evaluate the psychometric properties of the French version of the BPII 2.0, including its reliability and validity.
Detailed description
To address our primary outcome described above, an analytical observational design has been chosen as no intervention is applied to the subjects under study. The prospective study will confirm our hypothesis for objective 2, which is the validation of the questionnaire translated into French.
Study Population and Sample
The target population for this study consists of all patients with patellofemoral instability whose native language is French. Due to the difficulty of accessing such a large pool of patients, we will use an accessible population, specifically all French-speaking patients with patellofemoral instability who consult with an orthopedic surgeon at the Centre Hospitalier Universitaire de la Santé (CHUS) in Fleurimont, Hôtel-Dieu Hospital, or the Shriners Hospitals for Children - Canada in Montreal.
Selection Criteria
For the pre-test during the translation stage, all individuals aged 14 years or older, whose native language is French, are being followed for a knee condition at the CHUS outpatient clinic or Hôtel-Dieu Hospital, and who are willing to participate in the validation of the BPII 2.0 questionnaire translation will be included. No specific diagnosis of patellofemoral instability is required.
For the validation stage, the project will be presented to all patients at the CHUS Fleurimont, Hôtel-Dieu Hospital, or Shriners Hospitals for Children in Montreal, who are diagnosed with patellofemoral instability by an orthopedic surgeon and meet the criteria listed below. Patients with other pathologies of the affected lower limb or disease progression will be excluded to avoid confounding factors impacting functional quality of life. Also, those answering fewer than 19 questions will be excluded, as this corresponds to an invalid score according to studies of the test in English (4,6). To improve recruitment rates, we are making the project multicentric, and the orthopedic department at Shriners Hospitals for Children in Montreal will participate in the validation phase.
Inclusion Criteria
Patients aged 14 years and older with a new diagnosis of patellofemoral instability confirmed by an orthopedic surgeon
With conservative and/or surgical treatment
Patients fluent in both oral and written French
Exclusion Criteria
Patients who are unable to understand and/or respond to the questionnaire
Patients with another diagnosis or knee pathology under study (e.g., complex ligament tear, gonarthrosis)
Patients with another diagnosis or lower limb pathology under study with secondary functional impairment (e.g., coxarthrosis)
Patients with a change in the condition of the affected lower limb
Exclusion from test-retest reliability calculations if symptoms of patellofemoral instability worsen or new involvement of this lower limb occurs between T0 and T1
Exclusion from the response to change calculation if new involvement of the lower limb (e.g., ipsilateral lower limb trauma) occurs after treatment, i.e., between T0 and T2
Patients answering fewer than 19 questions (out of 23)
Sampling
To recruit eligible patients for the study, we will proceed with a non-probability convenience sampling approach.
For the first stage of translation (pre-test), all individuals who meet the criteria listed above will be included. For the second stage of validation, we will present the study to all patients who meet the selection criteria and present at the outpatient clinics of CHUS, Hôtel-Dieu Hospital, and Shriners Hospitals for Children in Montreal. This approach does not guarantee the representativeness of the population with patellofemoral instability, but it will not impact the validation of the functional measurement tool. This method will allow us to recruit a sufficient number of patients within a reasonable time frame. There are no confounding factors involved in the sampling of the population, as the goal of this study is the qualitative validation of the test, not measuring the treatment effect.
Recruitment
Participant recruitment will be on a voluntary basis. For the pre-test translation stage, patients will be recruited at the orthopedic outpatient clinic of CHUS Fleurimont or Hôtel-Dieu Hospital. For the validation stage, at the time of diagnosis, the orthopedic surgeon or resident at CHUS Fleurimont or Hôtel-Dieu Hospital who confirms patellofemoral instability will introduce the research project to the patient and verify if they meet the established selection criteria. If available at the participating center, the orthopedic surgeon or resident will have the patient sign a contact authorization form, if the research assistant is unavailable, to indicate whether the patient agrees to meet with the research assistant (Appendix 3). If the patient agrees to meet the research assistant, they will receive all relevant information about the research project. Together with the research assistant, the patient will be able to freely consent to their inclusion or exclusion from the research project by signing the informed consent form (refer to the consent form for the research project). In the case that the contact authorization form is unavailable, the research assistant will approach the patient after confirmation of the patellofemoral instability diagnosis during their clinic appointment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| validation | – | –person with patellar instability that will respond to the questionnaires |
Who may qualify
- Ages
- 14 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients consulting at the CHUS in Sherbrooke or at the Schriners Hospital in Montreal for patellar instability
Key inclusion criteria (2 listed)
- patient diagnosed with patellar instability with conservative or surgical treatment
- fluent in both spoken and written French
Key exclusion criteria (5 listed)
- Patients who are unable to understand and/or respond to the questionnaire
- Patients with another diagnosis or knee pathology under study (e.g., complex ligament tear of the knee, gonarthrosis)
- Patients with another diagnosis or lower limb pathology under study with secondary functional impairment (e.g., coxarthrosis)
- Patients with a change in the condition of the lower limb under study a. Exclusion from test-retest reliability calculations if symptoms of patellofemoral instability worsen or if there is new involvement of this lower limb between T0 and T1 b. Exclusion from response to change calculations if new involvement of the lower limb (e.g., ipsilateral lower limb trauma) occurs after treatment, i.e., between T0 and T2
- Patients answering fewer than 19 questions (out of 23 questions)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Questionnaire Banff Patellar Instability 2.0 Index in French
Time frame: Baseline, 1 week and 6 month post intervention
Questionnaire. (0-100 (0 = Worst, 100 = Best))
Questionnaire Anterior Knee Pain Scale (Kujala)
Time frame: Baseline and 6 month post intervention
Questionnaire. (0-100 (0 = Worst, 100 = Best))
Socio-Demographic
Time frame: Baseline
Age, Sex, Time since symptoms, Scolarship, Nationality
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2025.
- Individual participant dataSharing planned: Undecided. This was not mention in the consent form as required in our REB. We could share the data on demand but not on public registry
Related trials for Patellar Instability
Enrolling by invitation
Pediatric and Adolescent Patellar Instability
Patellar Instability
RecruitingObservational study
JUPITER 4.0 - Risk Factors for Failure of Isolated Medial Patellofemoral Ligament Reconstruction
Patellar Dislocation, Recurrent, Patellar Dislocation
Recruiting
Comparison of Dynamic and Static Medial Patellofemoral Ligament Operation Technique for Recurrent Patellar Dislocation
Patellar Instability
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
François Vézina, Doctor principal investigator
Université de Sherbrooke
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Patellar Instability, run by Université de Sherbrooke at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Questionnaire Banff Patellar Instability 2.0 Index in French (time frame: Baseline, 1 week and 6 month post intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2025.